PhaseBio Pharmaceuticals (NASDAQ: PHAS)
Some price data may be temporarily unavailable.
PhaseBio Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
PhaseBio Pharmaceuticals Company Info
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
News & Analysis
2 Ultra-High-Growth Stocks to Buy Now
Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.
Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today
The company made two major announcements in the last 24 hours.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.